{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T23:34:41Z","timestamp":1784244881721,"version":"3.55.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,1,26]],"date-time":"2023-01-26T00:00:00Z","timestamp":1674691200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,26]],"date-time":"2023-01-26T00:00:00Z","timestamp":1674691200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinik M\u00fcnchen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:title>Abstract\n<\/jats:title><jats:sec>\n                <jats:title>Purpose of Review<\/jats:title>\n                <jats:p>Apheresis is a treatment option for severe dyslipidemia which has been introduced approximately 40\u00a0years ago to clinical practice. This article reviews recent apheresis research progresses, including apheresis for elevated LDL-cholesterol and elevated lipoprotein(a).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Recent Findings<\/jats:title>\n                <jats:p>While the role of apheresis in treating more common forms of LDL-hypercholesterolemia has been reduced due to the development of new, very potent LDL-lowering drugs, it still plays an important role in treating patients with homozygous familial hypercholesterolemia and patients with severe lipoprotein(a) elevation. One apheresis session can decrease LDL-cholesterol, apoB, and lipoprotein(a) by approximately 65%, which results in a time averaged reduction of 30\u201350%. Although time-consuming, and expensive regular apheresis is very well tolerated and has been proven safe for decades.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Summary<\/jats:title>\n                <jats:p>Apheresis remains a treatment option for severe dyslipidemia, especially in homozygous familial hypercholesterolemia and elevated lipoprotein(a), if other forms of therapy fail to achieve targets.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11883-023-01081-7","type":"journal-article","created":{"date-parts":[[2023,1,26]],"date-time":"2023-01-26T07:02:36Z","timestamp":1674716556000},"page":"77-83","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Apheresis: What Should a Clinician Know?"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9873-0412","authenticated-orcid":false,"given":"Klaus G.","family":"Parhofer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,26]]},"reference":[{"key":"1081_CR1","doi-asserted-by":"publisher","first-page":"4791","DOI":"10.1093\/eurheartj\/ehab551","volume":"47","author":"HN Ginsberg","year":"2021","unstructured":"Ginsberg HN, Packard CJ, Chapman MJ, Boren J, Aguilar-Salinas CA, Averna M, et al. Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society. Eur Heart J. 2021;47:4791\u20134806.","journal-title":"Eur Heart J."},{"key":"1081_CR2","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1001\/jama.2009.801","volume":"301","author":"PR Kamstrup","year":"2009","unstructured":"Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA. 2009;301:2331\u20139.","journal-title":"JAMA"},{"key":"1081_CR3","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41:111\u201388.","journal-title":"Eur Heart J"},{"key":"1081_CR4","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/S0140-6736(75)92193-5","volume":"1","author":"GR Thompson","year":"1975","unstructured":"Thompson GR, Lowenthal R, Myant NB. Plasma exchange in the management of homozygous familial hypercholesterolaemia. Lancet. 1975;1:1208\u201311.","journal-title":"Lancet"},{"key":"1081_CR5","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s11883-019-0787-5","volume":"21","author":"G Thompson","year":"2019","unstructured":"Thompson G, Parhofer KG. Current role of lipoprotein apheresis. Curr Atheroscler Rep. 2019;21:26.","journal-title":"Curr Atheroscler Rep"},{"key":"1081_CR6","doi-asserted-by":"crossref","unstructured":"Parhofer KG, Von Stritzky B, Pietschmann N, Dorn C, Paar D. PEARL: a non-interventional study of real-world alirocumab use in German clinical practice.\u00a0Drugs - Real World Outcomes. 2019;6(3):115\u201323.\u00a0","DOI":"10.1007\/s40801-019-0158-0"},{"key":"1081_CR7","doi-asserted-by":"publisher","first-page":"3588","DOI":"10.1093\/eurheartj\/ehw388","volume":"37","author":"PM Moriarty","year":"2016","unstructured":"Moriarty PM, Parhofer KG, Babirak SP, Cornier MA, Duell PB, Hohenstein B, et al. Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial. Eur Heart J. 2016;37:3588\u201395.","journal-title":"Eur Heart J"},{"key":"1081_CR8","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1177\/2047487318792626","volume":"25","author":"MG Zenti","year":"2018","unstructured":"Zenti MG, Altomari A, Lupo MG, Botta M, Bonora E, Corsini A, et al. From lipoprotein apheresis to proprotein convertase subtilisin\/kexin type 9 inhibitors: impact on low-density lipoprotein cholesterol and C-reactive protein levels in cardiovascular disease patients. Eur J Prev Cardiol. 2018;25:1843\u201351.","journal-title":"Eur J Prev Cardiol"},{"key":"1081_CR9","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.atherosclerosis.2004.01.017","volume":"174","author":"C Otto","year":"2004","unstructured":"Otto C, Geiss HC, Empen K, Parhofer KG. Long-term reduction of C-reactive protein concentration by regular LDL apheresis. Atherosclerosis. 2004;174:151\u20136.","journal-title":"Atherosclerosis"},{"key":"1081_CR10","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1097\/MOL.0b013e3283402f53","volume":"21","author":"GR Thompson","year":"2010","unstructured":"Thompson GR, Catapano A, Saheb S, Atassi-Dumont M, Barbir M, Eriksson M, et al. Severe hypercholesterolaemia: therapeutic goals and eligibility criteria for LDL apheresis in Europe. Curr Opin Lipidol. 2010;21:492\u20138.","journal-title":"Curr Opin Lipidol"},{"key":"1081_CR11","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1002\/jca.20299","volume":"26","author":"JL Winters","year":"2011","unstructured":"Winters JL. Lipid apheresis, indications, and principles. J Clin Apher. 2011;26:269\u201375.","journal-title":"J Clin Apher"},{"key":"1081_CR12","unstructured":"GBA GB-A. Apheresis for elevated LDL-cholesterol. 2003.\u00a0https:\/\/www.g-ba.de\/downloads\/39-261-64\/2003-07-09-bub-apheresen.pdf. Accessed 23 Jan 2023."},{"key":"1081_CR13","unstructured":"GBA GB-A. Apheresis for elevated lipoprotein(a). 2013.\u00a0https:\/\/www.g-ba.de\/downloads\/39-261-1632\/2013-01-17_MVV-RL-DokIndApherese_BAnz.pdf. Accessed 23 Jan 2023."},{"key":"1081_CR14","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.jacl.2011.03.001","volume":"5","author":"AC Goldberg","year":"2011","unstructured":"Goldberg AC, Hopkins PN, Toth PP, Ballantyne CM, Rader DJ, Robinson JG, et al. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011;5:133\u201340.","journal-title":"J Clin Lipidol"},{"key":"1081_CR15","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.atherosclerosis.2008.02.009","volume":"198","author":"GR Thompson","year":"2008","unstructured":"Thompson GR. Recommendations for the use of LDL apheresis. Atherosclerosis. 2008;198:247\u201355.","journal-title":"Atherosclerosis"},{"key":"1081_CR16","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.pathol.2018.10.016","volume":"51","author":"E Waldmann","year":"2019","unstructured":"Waldmann E, Parhofer KG. Apheresis for severe hypercholesterolaemia and elevated lipoprotein(a). Pathology. 2019;51:227\u201332.","journal-title":"Pathology"},{"key":"1081_CR17","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1111\/j.1525-1594.1991.tb00771.x","volume":"15","author":"SN Pokrovsky","year":"1991","unstructured":"Pokrovsky SN, Adamova I, Afanasieva OY, Benevolenskaya GF. Immunosorbent for selective removal of lipoprotein (a) from human plasma: in vitro study. Artif Organs. 1991;15:136\u201340.","journal-title":"Artif Organs"},{"key":"1081_CR18","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/S0002-9149(98)00692-4","volume":"82","author":"H Mabuchi","year":"1998","unstructured":"Mabuchi H, Koizumi J, Shimizu M, Kajinami K, Miyamoto S, Ueda K, et al. Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group. Am J Cardiol. 1998;82:1489\u201395.","journal-title":"Am J Cardiol"},{"key":"1081_CR19","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/S0140-6736(95)92961-4","volume":"345","author":"GR Thompson","year":"1995","unstructured":"Thompson GR, Maher VM, Matthews S, Kitano Y, Neuwirth C, Shortt MB, et al. Familial hypercholesterolaemia regression study: a randomised trial of low-density-lipoprotein apheresis. Lancet. 1995;345:811\u20136.","journal-title":"Lancet"},{"key":"1081_CR20","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.atherosclerosissup.2012.10.015","volume":"14","author":"MS Safarova","year":"2013","unstructured":"Safarova MS, Ezhov MV, Afanasieva OI, Matchin YG, Atanesyan RV, Adamova IY, et al. Effect of specific lipoprotein(a) apheresis on coronary atherosclerosis regression assessed by quantitative coronary angiography. Atheroscler Suppl. 2013;14:93\u20139.","journal-title":"Atheroscler Suppl"},{"key":"1081_CR21","doi-asserted-by":"crossref","unstructured":"Safarova MS, Nugent AK, Gorby L, Dutton JA, Thompson WJ, Moriarty PM. Effect of lipoprotein apheresis on progression of carotid intima-media thickness in patients with severe hypercholesterolemia. Am J Cardiol. 2022;177:22\u20137.","DOI":"10.1016\/j.amjcard.2022.05.002"},{"key":"1081_CR22","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1093\/eurheartj\/ehx178","volume":"38","author":"TZ Khan","year":"2017","unstructured":"Khan TZ, Hsu LY, Arai AE, Rhodes S, Pottle A, Wage R, et al. Apheresis as novel treatment for refractory angina with raised lipoprotein(a): a randomized controlled cross-over trial. Eur Heart J. 2017;38:1561\u20139. Study shows improvement in mycardial perfusion reserve (MRI) with 3 months of apheresis in patients with elevated lipoprotein(a) using a randomized, sham-apheresis controlled setting.","journal-title":"Eur Heart J"},{"key":"1081_CR23","first-page":"229","volume":"6","author":"BR Jaeger","year":"2009","unstructured":"Jaeger BR, Richter Y, Nagel D, Heigl F, Vogt A, Roeseler E, et al. Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events. Nat Clin Pract Cardiovasc Med. 2009;6:229\u201339.","journal-title":"Nat Clin Pract Cardiovasc Med"},{"key":"1081_CR24","doi-asserted-by":"publisher","first-page":"2567","DOI":"10.1161\/CIRCULATIONAHA.113.002432","volume":"128","author":"J Leebmann","year":"2013","unstructured":"Leebmann J, Roeseler E, Julius U, Heigl F, Spitthoever R, Heutling D, et al. Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study. Circulation. 2013;128:2567\u201376.","journal-title":"Circulation"},{"key":"1081_CR25","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1111\/aor.12135","volume":"38","author":"A Rosada","year":"2014","unstructured":"Rosada A, Kassner U, Vogt A, Willhauck M, Parhofer K, Steinhagen-Thiessen E. Does regular lipid apheresis in patients with isolated elevated lipoprotein(a) levels reduce the incidence of cardiovascular events? Artif Organs. 2014;38:135\u201341.","journal-title":"Artif Organs"},{"key":"1081_CR26","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1016\/j.jacl.2019.09.010","volume":"13","author":"PM Moriarty","year":"2019","unstructured":"Moriarty PM, Gray JV, Gorby LK. Lipoprotein apheresis for lipoprotein(a) and cardiovascular disease. J Clin Lipidol. 2019;13:894\u2013900.","journal-title":"J Clin Lipidol"},{"key":"1081_CR27","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.atherosclerosissup.2017.05.011","volume":"30","author":"MV Ezhov","year":"2017","unstructured":"Ezhov MV, Afanasieva OI, Il\u2019ina LN, Safarova MS, Adamova IY, Matchin YG, et al. Association of lipoprotein(a) level with short- and long-term outcomes after CABG: The role of lipoprotein apheresis. Atheroscler Suppl. 2017;30:187\u201392.","journal-title":"Atheroscler Suppl"},{"key":"1081_CR28","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.transci.2018.07.015","volume":"57","author":"F Bigazzi","year":"2018","unstructured":"Bigazzi F, Sbrana F, Berretti D, Maria Grazia Z, Zambon S, Fabris A, et al. Reduced incidence of cardiovascular events in hyper-Lp(a) patients on lipoprotein apheresis. The G.I.L.A. (Gruppo Interdisciplinare Aferesi Lipoproteica) pilot study. Transfus Apher Sci. 2018;57:661\u20134.","journal-title":"Transfus Apher Sci."},{"key":"1081_CR29","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1194\/jlr.R056549","volume":"57","author":"E Waldmann","year":"2016","unstructured":"Waldmann E, Parhofer KG. Lipoprotein apheresis to treat elevated lipoprotein (a). J Lipid Res. 2016;57:1751\u20137.","journal-title":"J Lipid Res"},{"key":"1081_CR30","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s11789-017-0089-9","volume":"12","author":"VJ Schettler","year":"2017","unstructured":"Schettler VJ, Neumann CL, Peter C, Zimmermann T, Julius U, Roeseler E, et al. The German Lipoprotein Apheresis Registry (GLAR) - almost 5 years on. Clin Res Cardiol Suppl. 2017;12:44\u20139. Large registry based data set on the use of apheresis in real world setting in Germany.","journal-title":"Clin Res Cardiol Suppl"}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-023-01081-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11883-023-01081-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-023-01081-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,22]],"date-time":"2023-02-22T22:06:14Z","timestamp":1677103574000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11883-023-01081-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,26]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["1081"],"URL":"https:\/\/doi.org\/10.1007\/s11883-023-01081-7","relation":{},"ISSN":["1523-3804","1534-6242"],"issn-type":[{"value":"1523-3804","type":"print"},{"value":"1534-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,26]]},"assertion":[{"value":"8 December 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Klaus G. Parhofer reports personal fees from Akcea, Amarin, Amgen, and Daiichi-Sankyo; grants and personal fees from Novartis and Sanofi; and personal fees from SOBI, during the conduct of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}